Use of protein array technology to investigate receptor tyrosine kinases activated in hepatocellular carcinoma.
Shi Liu,Jian Gong,Asahiro Morishita,Takako Nomura,Hisaaki Miyoshi,Joji Tani,Kiyohito Kato,Hirohito Yoneyama,Akihiro Deguchi,Hirohito Mori,Shima Mimura,Kei Nomura,Takashi Himoto,Kazushi Deguchi,Keiichi Okano,Kunihiko Izuishi,Yasuyuki Suzuki,Yoshio Kushida,Reiji Haba,Hisakazu Iwama,Tsutomu Masaki +20 more
Reads0
Chats0
TLDR
Protein array technology is proposed as a tool for detecting the expression of activated RTKs and identifying an effective RTK-based therapy and suggesting that ErbB2 is activated in HCC and that trastuzumab may play a role in the treatment of this disease.Abstract:
Receptor tyrosine kinases (RTKs) play a role in various processes, including cell growth, differentiation, apoptosis and carcinogenesis. RTKs are activated in various types of cancers, including breast, stomach, colon, pancreas and liver cancer and hepatocellular carcinoma (HCC). In the present study, protein array technology was used to analyze the expression status of various RTKs activated in HCC. The expression of activated RTKs was examined in the HCC cell lines, Alex, HuH7, Li-7, Hep3B, HLE and HLF; in the human normal hepatocyte cell line, hNHeps; and in human HCC and adjacent non-cancerous tissues. Of the 42 different phospho-RTKs, 15 (ErbB2, ErbB3, ErbB4, FGFR2α, FGFR3, insulin R, Mer, PDGFRβ, c-Ret, ROR2, Tie, TrkA, VEGFR3, EphA1 and EphA4) were activated in some of the cancer cell lines studied. Among these, only ErbB2 was activated in all the HCC cell lines examined. Also, in vitro experiments were performed in subcutaneous HCC-bearing athymic nude mice to determine the therapeutic effects of inhibiting ErbB2 activation using the ErbB2-targeting drug trastuzumab. The results revealed that trastuzumab markedly suppressed the growth of HCC. These data suggest that ErbB2 is activated in HCC and that trastuzumab may play a role in the treatment of this disease. In addition, the use of protein array technology is proposed as a tool for detecting the expression of activated RTKs and identifying an effective RTK-based therapy.read more
Citations
More filters
Journal ArticleDOI
Artemin is hypoxia responsive and promotes oncogenicity and increased tumor initiating capacity in hepatocellular carcinoma
Min Zhang,Weijie Zhang,Zhengsheng Wu,Shu-Min Liu,Linchong Sun,Yanghao Zhong,Xiao Zhang,Xiangjun Kong,Pengxu Qian,Huafeng Zhang,Peter E. Lobie,Tao Zhu +11 more
TL;DR: A novel HIF-1α/ARTN axis promoting CSC-like behavior in hypoxic environments is identified which implicates ARTN as a valuable therapeutic target for HCC.
Journal ArticleDOI
Comparative study of ROR2 and WNT5a expression in squamous/adenosquamous carcinoma and adenocarcinoma of the gallbladder.
Zhengchun Wu,Li Xiong,Lingxiang Wang,Xiongying Miao,Ziru Liu,Daiqiang Li,Qiong Zou,Kuijie Liu,Hua Zhao,Zhulin Yang +9 more
TL;DR: SC/ASC or AC patients with positive ROR2 or WNT5a expression generally have a poor prognosis and were negatively correlated with the postoperative survival rate and positively correlated with mortality, which are risk factors and independent prognostic predictors.
Journal ArticleDOI
Expression of angiogenic factors in hepatocarcinogenesis: Identification by antibody arrays
Takako Nomura,Asahiro Morishita,Gong Jian,Shima Mimura,Kiyohito Kato,Kei Nomura,Joji Tani,Hisaaki Miyoshi,Hirohito Yoneyama,Teppei Sakamoto,Koji Fujita,Emiko Maeda,Hideki Kobara,Hirohito Mori,Hisakazu Iwama,Tsutomu Masaki +15 more
TL;DR: Data suggest that the upregulation of either IL-8 or bFGF is closely related to the transition from liver cirrhosis into HCC, and the analysis of the expression of these cytokines using protein arrays may identify novel therapies for individual patients with HCC.
Dissertation
Vandetanib-eluting beads for the treatment of liver tumours
TL;DR: The results are shown in the table below, which summarizes the results of the studies carried out at the 2015 USGS workshop on quantitative hazard assessments of earthquake-triggered landsliding and liquefaction in the Czech Republic.
References
More filters
Journal ArticleDOI
Global cancer statistics, 2002.
TL;DR: There are striking variations in the risk of different cancers by geographic area, most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
Classification of chronic hepatitis: diagnosis, grading and staging.
TL;DR: Recombinant human alpha-interferon in patients with chronic nonA-nonB hepatitis and factors predictive of response to interferon alpha therapy in HCV infection are studied.
Journal ArticleDOI
Global cancer statistics in the year 2000
TL;DR: The most common cancers in terms of new cases were lung (1.2 million), breast (1,05 million), colorectal (945 000), stomach (876'000), and liver (564'000).
Journal ArticleDOI
Protein Tyrosine Kinase Structure and Function
TL;DR: This review will highlight the important results that have emerged from high-resolution structural studies of protein tyrosine kinases and provide a molecular basis for understanding the mechanisms by which receptor and nonreceptor PTKs are regulated.
Related Papers (5)
MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Leandro Venturutti,R I Cordo Russo,Martín A. Rivas,María Florencia Mercogliano,Franco Izzo,Robert H. Oakley,Matías G. Pereyra,M De Martino,Cecilia J. Proietti,Patricio Yankilevich,Juan Carlos Roa,Juan Carlos Roa,Pablo Guzmán,Eduardo Cortese,Daniel H. Allemand,Tim H M Huang,Eduardo H. Charreau,John A. Cidlowski,Roxana Schillaci,Patricia V. Elizalde +19 more